Medrogestone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Medrogestone
Accession Number
DB09124
Type
Small Molecule
Groups
Approved
Description

Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestin, a synthetic drug with similar effects as progesterone, a hormone involved in the menstrual cycle and pregnancy. As of 2010, it is no longer available in Germany or Austria.

Structure
Thumb
Synonyms
Not Available
External IDs
AY 62022 / AY-13615 / AY-13615S / AY-62022 / NSC-123018
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Colprone Tab 5mgTablet5 mgOralWyeth Ayerst Canada Inc.1996-10-252001-08-30Canada
Colprone Tab 5mgTablet5 mgOralAyerst Laboratories1969-12-311997-08-15Canada
Categories
UNII
077DN93G5B
CAS number
977-79-7
Weight
Average: 340.507
Monoisotopic: 340.24023027
Chemical Formula
C23H32O2
InChI Key
HCFSGRMEEXUOSS-JXEXPEPMSA-N
InChI
InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1
IUPAC Name
(1S,2R,10R,11S,14S,15S)-14-acetyl-2,8,14,15-tetramethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-6,8-dien-5-one
SMILES
[H][[email protected]@]12CC[[email protected]](C)(C(C)=O)[[email protected]@]1(C)CC[[email protected]@]1([H])[[email protected]@]2([H])C=C(C)C2=CC(=O)CC[[email protected]]12C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Medrogestone.Approved
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Medrogestone.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Medrogestone.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Medrogestone.Experimental
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Medrogestone.Investigational
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Medrogestone.Approved
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medrogestone.Approved
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Medrogestone.Approved, Investigational, Withdrawn
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Medrogestone.Approved, Investigational
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Medrogestone.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Medrogestone.Approved, Investigational
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medrogestone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medrogestone.Approved
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Medrogestone.Approved, Investigational
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Medrogestone.Approved, Nutraceutical, Vet Approved
Conestat alfaMedrogestone may increase the thrombogenic activities of Conestat alfa.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Medrogestone.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Medrogestone.Experimental
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medrogestone.Approved
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Medrogestone.Approved
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Medrogestone.Approved, Withdrawn
DarexabanThe therapeutic efficacy of Darexaban can be decreased when used in combination with Medrogestone.Investigational
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Medrogestone.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Medrogestone.Approved
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Medrogestone.Approved, Vet Approved
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Medrogestone.Approved
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Medrogestone.Approved
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Medrogestone.Approved
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Medrogestone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Medrogestone.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Medrogestone.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Medrogestone.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medrogestone.Approved, Investigational
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Medrogestone.Approved, Vet Approved
EdoxabanThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Medrogestone.Approved
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medrogestone.Approved
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Medrogestone.Withdrawn
Ferulic acidThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Medrogestone.Experimental
FluindioneThe therapeutic efficacy of Fluindione can be decreased when used in combination with Medrogestone.Investigational
FondaparinuxThe therapeutic efficacy of Fondaparinux can be decreased when used in combination with Medrogestone.Investigational
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Medrogestone.Approved, Investigational
GabexateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Medrogestone.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Medrogestone.Experimental
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Medrogestone.Approved, Investigational
Human C1-esterase inhibitorMedrogestone may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
IdraparinuxThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Medrogestone.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Medrogestone.Experimental
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Medrogestone.Approved
LetaxabanThe therapeutic efficacy of Letaxaban can be decreased when used in combination with Medrogestone.Investigational
MelagatranThe therapeutic efficacy of Melagatran can be decreased when used in combination with Medrogestone.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Medrogestone.Experimental
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medrogestone.Approved
NafamostatThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Medrogestone.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Medrogestone.Experimental, Investigational
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Medrogestone.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Medrogestone.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medrogestone.Approved, Vet Approved
Pentaerythritol TetranitrateThe therapeutic efficacy of Pentaerythritol Tetranitrate can be decreased when used in combination with Medrogestone.Approved
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medrogestone.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Medrogestone.Experimental
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Medrogestone.Approved, Investigational
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Medrogestone.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Medrogestone.Experimental
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Medrogestone.Approved
Protein S humanThe therapeutic efficacy of Protein S human can be decreased when used in combination with Medrogestone.Approved
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Medrogestone.Approved
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Medrogestone.Approved, Investigational
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medrogestone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Medrogestone.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Medrogestone.Approved, Investigational
TroxerutinThe therapeutic efficacy of Troxerutin can be decreased when used in combination with Medrogestone.Investigational
UlipristalThe therapeutic efficacy of Medrogestone can be decreased when used in combination with Ulipristal.Approved
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Medrogestone.Approved
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Medrogestone.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
9949848
PubChem Substance
310265040
ChemSpider
8125459
ChEBI
135446
ChEMBL
CHEMBL2106825
ATC Codes
G03FB07 — Medrogestone and estrogenG03DB03 — Medrogestone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral5 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00404 mg/mLALOGPS
logP4.35ALOGPS
logP4.59ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)19.18ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity102.6 m3·mol-1ChemAxon
Polarizability40.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-oxosteroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives
Substituents
Progestogin-skeleton / 20-oxosteroid / Oxosteroid / 3-oxosteroid / Cyclohexenone / Cyclic ketone / Ketone / Organic oxygen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on September 23, 2015 10:20 / Updated on November 09, 2017 04:45